India, July 31 -- Shares of Karyopharm Therapeutics Inc. (KPTI) are tumbling about 68 percent on Friday morning after the company announced yesterday topline results from its Phase 3 XPORT-EC-042 trial, which failed to meet its primary endpoint of progression-free survival or PFS.
Shares of the company slipped 68.17 percent to $2.2350 on the Nasdaq, compared with the previous closing price of $7.01. The stock has traded in a 52-week range of $2.09 to $10.99.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....